Initially developed by Novo Nordisk in the 1990s, Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) selective agonist of the GHS-R1a receptor (ghrelin receptor), responsible for stimulating pulsatile growth hormone secretion without the cross-side effects characteristic of non-selective GHRPs
Boosts collagen, firms skin, non-greasy
Many of the positive vascular and cerebrovascular adaptations to RT can be linked back to reduced ROS production, improved antioxidant defenses, and reduced inflammation
Gallbladder disease, including cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder), has been reported in individuals using tirzepatide
Comprehensive Benefits of GHK-CU GHK-CU has been shown to influence a wide range of biological systems, making it a versatile component of regenerative therapy